LETTER TO THE EDITOR

CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients

Mengying Ke1,2†, Liqing Kang3†, Ling Wang2, Shu Yang2, Yajun Wang2, Haiyan Liu4, Chunyan Gu1,2*, Hongming Huang4* and Ye Yang2*

Abstract

The chimera antigen receptor (CAR) T cell therapy is a novel and potential targeted therapy and has achieved satisfactory efficacy in patients with relapsed or refractory multiple myeloma (MM) in recent years. However, cytokine release syndrome (CRS) and clinical efficacy have become the major obstacles which limit the application of CAR-T in clinics. To explore the potential biomarkers in plasma for evaluating CRS and clinical efficacy, we performed metabolomic and lipidomic profiling of plasma samples from 17 relapsed or refractory MM patients received CAR-T therapy. Our study showed that glycerophosphocholine (GPC), an intermediate of platelet-activating factor (PAF)-like molecule, was significantly decreased when the participants underwent CRS, and the remarkable elevation of lysophosphatidylcholines (lysoPCs), which were catalyzed by lysoPC acyltransferase (LPCAT) was a distinct metabolism signature of relapsed or refractory MM patients with prognostic value post-CAR-T therapy. Both GPC and lysoPC are involved in platelet-activating factor (PAF) remodeling pathway. Besides, these findings were validated by LPCAT1 expression, a key factor in the PAF pathway, associated with poor outcome in three MM GEP datasets of MM. In conclusion, CAR-T therapy alters PAF synthesis in MM patients, and targeting PAF remodeling may be a promising strategy to enhance MM CAR-T therapy.

Keywords: Platelet-activating factor, Multiple myeloma, CAR-T therapy, Cytokine release syndrome, LPCAT1

To the Editor,

Multiple myeloma (MM) is still an incurable hematological malignancy, as most of MM patients eventually relapse or become refractory [1, 2]. Strikingly, the CAR-T cell therapy has achieved satisfactory efficacy in patients with relapsed or refractory MM in recent years [3]. However, cytokine release syndrome (CRS) and clinical efficacy have become the major obstacles which limit the application of CAR-T in clinics [4]. To explore the potential biomarkers in plasma, we uniquely imported metabolomics analytic techniques and examined the profile changes of metabolites and lipids in plasma from 17 relapsed or refractory MM patients post-CAR-T therapy (Fig. 1a). The clinical characteristics of 17 participants are presented in Additional file 1: Table S1.

We first detected the differential metabolites in CRS group including participants with CRS within the first week post-infusion and without CRS at day 30 post-infusion (Additional file 1: Fig. S1) and comparative efficacy group (CE group) including participants with remission and non-remission at day 30 post-infusion
We further conducted targeted metabolomics to explore LPCs volume, and as shown in Fig. 2a, disordered metabolic pathways were involved in PAF synthesis [12]. Moreover, the area under receiver operating characteristic (ROC) curve of LPC(16:0) was 0.9833, suggesting that LPC could serve as a potential plasma biomarker for prognosis of relapsed or refractory MM (Fig. 2b). Then, to validate reliable plasma biomarkers for prognosis of CAR-T therapy (Additional file 3: Table S4), we detected TIC, PCA, and OPLS-DA (Additional file 3: Fig. S3) of lipidomic profiling in CE group represented in Fig. 2c–e, respectively. LPC(O-24:0), LPC(20:4) and LPC(16:1/0:0), significantly heightened in relieved participants at day 30 post-CAR-T therapy among 44 differential lipids (Fig. 2f–i). Heatmap showed marked elevation of the three LPCs compared with top 20 differential lipids (Fig. 2j). In addition, LPCAT1, one of LPCAT family members, is crucial for lipid droplet remodeling and LPC metabolism [11]. Therefore, we assessed the gene expression of LPCAT1 in normal people (NP), MGUS and MM bone marrow plasma cells based on GEP dataset. The LPCAT1 mRNA was remarkably increased in MM patients compared with MGUS and NP (p = 0.0332; Fig. 2k). Furthermore, unlike other members in LPCAT family (Additional file 4: Fig. S4), higher LPCAT1 expression was associated with poor overall survival (OS) in MM patients (TT2, GSE2658) (p = 0.0378; Fig. 2l). This finding was also verified in other two independent cohorts, HOVON-65 clinical trial (p = 0.0052; Fig. 2m) and the APEX phase III clinical trial (p = 0.0003; Fig. 2n). Additionally, we found that LPCAT1 mRNA was significantly increased in relapsed MM patients compared with newly diagnosed patients from TT2 cohort (GSE38627) (p = 0.0065; Fig. 2o).

Our study demonstrated that CAR-T therapy could inhibit the remodeling pathway of PAF synthesis via inactivating LPCAT1 and lead to the elevation of plasma LPCs. We also propose that LPCAT1 may act as an oncogene in MM, which is available to be targeted in clinics particularly in CAR-T therapy. Collectively, targeting PAF remodeling may be a promising strategy to enhance MM CAR-T therapy.
(See figure on previous page.)

**Fig. 2** The lipids characteristics of the validation set. a PAF synthesis pathway. b ROC analysis for LPC(16:0) (AUC: 0.9833, 95% confidence interval: 0.9322–1.0000). c Typical chromatograms of TIC in plasma samples from comparative efficacy group. d Score plot of PCA based on the data of ESI+ mode from comparative efficacy group. e Score plot of OPLS-DA based on the data of ESI+ mode from comparative efficacy group. f Volcano plot based on the data of ESI+ mode from comparative efficacy group. g–i Changes of LPC(O-24:0), LPC(20:4) and LPC(16:1/0:0) contents in plasma of comparative efficacy group. j Heatmap showed that LPC(O-24:0), LPC(20:4) and LPC(16:1/0:0) were significantly increased that were identified from the comparison of R vs NR. k The mRNA level of LPCAT1 in bone marrow plasma cells from NP (n = 22), MGUS (n = 44) and MM (n = 500). LPCAT1 expression was significantly increased in MM samples by ordinary one-way ANOVA test. l–n High LPCAT1 expression in MM patients was correlated with poor OS in TT2 cohort, HOVON-65 clinical trial and APEX phase III clinical trial by log-rank test. o The expression of LPCAT1 mRNA at baseline (previously published under GSE2685, n = 351) and relapse patients (n = 130). LPCAT1 expression was markedly increased in the relapsed MM patients by log-rank test. (*p < 0.05, **p < 0.01)

**Abbreviations**

CAR: Chimera antigen receptor; MM: Multiple myeloma; CRS: Cytokine release syndrome; GPC: Glycerophosphocholine; PAF: Platelet-activating factor; LPC: Lysophosphatidylcholine; LPCAT: Lysophosphatidylcholine acyltransferase; GEP: Gene expression profiling; R: Remission; NR: Non-remission; ESI: Electrospray ionization; TIC: Total ion chromatograms; PCA: Principal component analysis; OPLS-DA: Orthogonal partial least squares discriminant analysis; VIP: Variable importance in the projection; FC: Fold change; KEGG: Kyoto encyclopedia of genes and genomes; ROC: Receiver operating characteristic; NP: Normal people; MGUS: Monoclonal gammopathy of undetermined significance; OS: Overall survival.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13045-021-01101-6.

Additional file 1. The characteristics of patients and plasma samples.

Additional file 2. Untargeted metabolomics.

Additional file 3. Lipidomics.

Additional file 4. GEP analysis of other 3 members in LPCAT family including LPCAT2, LPCAT3 and LPCAT4.

**Acknowledgements**

We thank Prof. Hongbo Wang, Prof. Jinjun Shan and Dr. Zhihua Song for providing equipment support. We thank Caihong Li, Zichen Luo, Weichen Xu, Yu He and Yang zhou for providing technical support.

**Authors’ contributions**

YY, CG and HH designed the project, integrated the data and revised the manuscript; MK, LK, HL, ZL, YZ collected plasma samples, performed experiments, analyzed the data and drafted the manuscript. All authors have read and approved the final version of the manuscript.

**Funding**

This work was supported by National Key R&D Program of China (No. 2020YFA0509400); Natural Science Foundation of Jiangsu Province BK20200097 (to CG), A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (Integration of Chinese and Western Medicine).

**Availability of data and materials**

All supporting data are included in the manuscript and supplemental files. Additional data are available upon reasonable request to the corresponding author.

**Declarations**

**Ethics approval and consent to participate**

All participants provided written informed consent in accordance with the approval of the ethics committee of the Affiliated Hospital of Nantong University (2018-K007) in agreement with the Declaration of Helsinki. Institutional approval was not required to publish this manuscript.

**Consent for publication**

Not applicable.

**Competing interests**

No potential conflicts of interest were disclosed.

**Author details**

1. Nanjing Hospital of Chinese Medicine affiliated to Nanjing University of Chinese Medicine, Nanjing, China. 2. School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing 210023, China. 3. Shanghai Unicar-Therapy Bio-Medicine Technology Co., Ltd, Shanghai, China. 4. Department of Hematology, The Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu, China.

**Received:** 14 April 2021  **Accepted:** 28 May 2021

**Published online:** 09 June 2021

**References**

1. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548–67. https://doi.org/10.1002/ajh.35791.
2. Jiang F, Tang X, Tang C, et al. HnRNP2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA. J Hematol Oncol. 2021;14(1):54. https://doi.org/10.1186/s13045-021-01066-6.
3. Yang Y, Li Y, Gu H, Dong M, Cai Z. Emerging agents and regimens for multiple myeloma. J Hematol Oncol. 2020;95(5):500. https://doi.org/10.1186/s13045-020-00980-5.
4. Bruno B, Wasch R, Engelhardt M, et al. European myeloma network perspective on CAR T-Cell therapies for multiple myeloma. Haematologica. 2021. https://doi.org/10.3324/haematol.2020.276402.
5. Ferracini M, Sahu RP, Hamson KA, et al. Topical photodynamic therapy induces systemic immunosuppression via generation of platelet-activating factor receptor ligands. J Invest Dermatol. 2015;135(1):321–3. https://doi.org/10.1038/jid.2014.313.
6. Chaitra VH, Jacob SP, Lakshminanth CL, et al. Modulation of inflammatory platelet-activating factor (PAF) receptor by the acyl analogue of PAF. J Lipid Res. 2018;59(11):2063–74. https://doi.org/10.1194/jlr.M085704.
7. Gill P, Jindal NL, Jagdis A, Vadas P. Platelets in the immune response: Revisiting platelet-activating factor in anaphylaxis. J Allergy Clin Immunol. 2015;135(6):1424–32. https://doi.org/10.1016/j.jaci.2015.04.019.
8. Silva Jr I, Chammas R, Lepique AP, Jancar SJ O. Platelet-activating factor (PAF) receptor as a promising target for cancer cell repopulation after radiotherapy. Oncogenesis. 2017;6(1):e296. https://doi.org/10.1038/oncsis.2016.90.

9. Tesfamariam B. Involvement of platelets in tumor cell metastasis. Pharmacol Ther. 2016;157:112–9. https://doi.org/10.1016/j.pharmthera.2015.11.005.

10. Kim HA, Kim KJ, Yoon SY, Lee HK, Im SY. Glutamine inhibits platelet-activating factor-mediated pulmonary tumour metastasis. Eur J Cancer. 2012;48(11):1730–8. https://doi.org/10.1016/j.ejca.2011.07.013.

11. Wang B, Tontonoz P. Phospholipid remodeling in physiology and disease. Annu Rev Physiol. 2019;81:165–88. https://doi.org/10.1146/annurev-physiol-020518-114444.

12. Lordan R, Tsoupras AB, Zabetakis I, Demopoulos CAJM. Forty years since the structural elucidation of platelet-activating factor (PAF): historical, current, and future research perspectives. Molecules. 2019,24(23):4414. https://doi.org/10.3390/molecules24234414.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.